Latest & greatest articles for valsartan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on valsartan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on valsartan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for valsartan

1. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trial

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trial 30002098 2018 07 13 1524-4539 2018 Jul 12 Circulation Circulation Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trial. CIRCULATIONAHA.118.034818 10.1161/CIRCULATIONAHA.118.034818 Background -Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced (...) ejection fraction, but its effects on kidney function and cardiac biomarkers in people with moderate-to-severe chronic kidney disease are unknown. Methods -UK HARP-III was a randomised double-blind trial which included 414 participants with an estimated glomerular filtration rate (GFR) 20-60 mL/min/1.73m 2 who were randomly assigned to sacubitril/valsartan 97/103 mg twice daily versus irbesartan 300 mg once daily. The primary outcome was measured GFR (mGFR) at 12 months using analysis of covariance

EvidenceUpdates2018

2. Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study.

Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study. OBJECTIVE: To perform an expedited assessment of cancer risk associated with exposure to N-nitrosodimethylamine (NDMA) through contaminated valsartan products. DESIGN: Nationwide cohort study. SETTING: Danish health registries on individual level prescription drug use, cancer occurrence, and hospital diagnoses. PARTICIPANTS: 5150 Danish patients with no history of cancer (...) , aged 40 years or older, and using valsartan at 1 January 2012 or initiating use between 1 January 2012 and 30 June 2017. Participants were followed from one year after cohort entry (lag time period) until experiencing a cancer outcome, death, migration, or end of study period (30 June 2018). Each participant's exposure to NDMA (ever exposure and predefined categories of cumulative valsartan exposure) was mapped out as a time varying variable while also applying a one year lag. MAIN OUTCOME MEASURES

BMJ2018

3. Valsartan

Valsartan Top results for valsartan - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for valsartan The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

4. EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity

EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity European Medicines Agency - News and Events - EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity Search for medicines Main navigation News and press releases EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity Press release 05/07/2018 EMA reviewing medicines containing valsartan from Zhejiang (...) Huahai following detection of an impurity Some valsartan medicines being recalled across the EU The European Medicines Agency (EMA) is reviewing medicines containing the active substance valsartan that is supplied by Zhejiang Huahai Pharmaceuticals, a company in Linhai, China. The review was triggered after the company detected an impurity, N-nitrosodimethylamine (NDMA), in the valsartan active substance which the company supplies to manufacturers producing some of the valsartan medicines available

European Medicines Agency - EPARs2018

5. Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design

Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design Impact of sacubitril–valsartan combination in patients withchronicheartfailure andsleep apnoeasyndrome: the ENTRESTO-SAS study design Dany Jaffuel 1 , Nicolas Molinari 2 , Philippe Berdague 3 , Atul Pathak 4 , Michel Galinier 5 , Marion Dupuis 6 , Jean-Etienne Ricci 7 , Jean-Pierre Mallet 1 , Arnaud Bourdin 1 and François Roubille 8 * 1 Department (...) of Montpellier, INSERM U1046, CNRS UMR, 9214, Montpellier, France Abstract Aims Sleep-disordered breathing (SDB)isahighlyprevalentco-morbidityinpatients withchronicheartfailure(CHF)andcan play a detrimental role in the pathophysiology course of CHF. However, the best way to manage SDB in CHF remains a matter of debate. Sacubitril–valsartan has been included in the 2016 European Society of Cardiology guidelines as an alternative to angiotensin-converting enzyme inhibitors to further reduce the risk

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

6. Insights into implementation of sacubitril/valsartan into clinical practice

Insights into implementation of sacubitril/valsartan into clinical practice Insights into implementation of sacubitril/valsartan into clinical practice Pieter Martens 1,2 , Hanne Beliën 1 , Matthias Dupont 1 and Wilfried Mullens 1,3 * 1 Department of Cardiology, Ziekenhuis Oost-Limburg, Schiepse Bos 63600, Genk, Belgium; 2 Doctoral School for Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium; 3 Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt (...) University, Diepenbeek, Belgium Abstract Background Sacubitril/valsartan signi?cantly reduced heart failure hospitalization and mortality in PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). However, real-world data from its use are lacking. Methods and results We retrospectively assessed all baseline and follow-up data of consecutive heart

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

7. Eligibility of sacubitril–valsartan in a real‐world heart failure population: a community‐based single‐centre study

Eligibility of sacubitril–valsartan in a real‐world heart failure population: a community‐based single‐centre study Eligibility of sacubitril–valsartan in a real-world heart failure population: a community-based single-centre study Helena Norberg 1,2 , Ellinor Bergdahl 2 and Krister Lindmark 2 * 1 Department of Pharmacology and Clinical Neuroscience, Umeå University, S-901 87, Umeå, Sweden; 2 Department of Public Health and Clinical Medicine, Umeå University, S-901 87, Umeå, Sweden (...) with a diagnosis of heart failure, 1924 (95%) had at least one echocardiography performed, and 401 patients had an ejection fraction of =35% at their latest examination. The major PARADIGM-HF criteria were applied, and 95 patients ful?lled all enrolment criteria and thus were eligible for sacubitril–valsartan. This corresponds to 5% of the overall heart failure population and 24% of the population with ejection fraction= 35%.The eligible patients weresigni?cantlyolder(73.2 ±10.3vs. 63.8±11.5years),had higher

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

8. The impact of a dose of the angiotensin receptor blocker valsartan on post‐myocardial infarction ventricular remodelling

The impact of a dose of the angiotensin receptor blocker valsartan on post‐myocardial infarction ventricular remodelling The impact of a dose of the angiotensin receptor blocker valsartan on post‐myocardial infarction ventricular remodelling - Park - 2018 - ESC Heart Failure - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search term Search Search term Search The full text of this article hosted at iucr.org is unavailable due (...) to technical difficulties. Original Research Article Open Access The impact of a dose of the angiotensin receptor blocker valsartan on post‐myocardial infarction ventricular remodelling Division of Cardiology, Department of Internal Medicine, Dong‐A University Hospital, Busan, Republic of Korea Corresponding Author E-mail address: Division of Cardiology, Department of Internal Medicine, Dong‐A University Hospital, Busan, Republic of Korea Correspondence to: Young‐Dae Kim, Regional Cardiovascular Center

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

9. Rationale and design of TRANSITION: a randomized trial of pre‐discharge vs. post‐discharge initiation of sacubitril/valsartan

Rationale and design of TRANSITION: a randomized trial of pre‐discharge vs. post‐discharge initiation of sacubitril/valsartan Rationale and design of TRANSITION: a randomized trial of pre‐discharge vs. post‐discharge initiation of sacubitril/valsartan - Pascual‐Figal - 2018 - ESC Heart Failure - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search term Search Search term Search The full text of this article hosted at iucr.org (...) is unavailable due to technical difficulties. Original Research Article Open Access Rationale and design of TRANSITION: a randomized trial of pre‐discharge vs. post‐discharge initiation of sacubitril/valsartan Corresponding Author E-mail address: Heart Failure and Heart Transplantation Unit, Cardiology Department, Virgen de la Arrixaca University Hospital, Universidad de Murcia, Murcia, Spain Correspondence to: Dr Domingo Pascual‐Figal, Heart Failure and Heart Transplantation Unit, Cardiology Department

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

10. Use of sacubitril/valsartan in acute decompensated heart failure: a case report

Use of sacubitril/valsartan in acute decompensated heart failure: a case report 29035000 2018 10 25 2018 11 13 2055-5822 5 1 2018 02 ESC heart failure ESC Heart Fail Use of sacubitril/valsartan in acute decompensated heart failure: a case report. 184-188 10.1002/ehf2.12219 Refractory heart failure typically requires costly long-term, continuous intravenous inodilator infusions while patients await mechanical circulatory support or cardiac transplantation. The combined angiotensin (...) receptor blocker-neprilysin inhibitor, sacubitril/valsartan, is a novel therapy that can increase levels of endogenous vasoactive peptides. This therapy has been recommended as an alternative agent in patients with chronic heart failure with reduced ejection fraction and New York Heart Association class II-III symptoms. Here, we report a case of a patient with refractory stage D heart failure with reduced ejection fraction who was successfully weaned off continuous intravenous inodilator support using sacubitril

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

11. Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients

Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients 29142906 2018 11 13 2356-6981 2017 2017 International journal of chronic diseases Int J Chronic Dis Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six (...) Observational Valsartan Studies with 15,282 Evaluable Patients. 9842450 10.1155/2017/9842450 We pooled data from 6 valsartan-related studies including 3,658 diabetic and 11,624 nondiabetic patients to evaluate blood pressure (BP) outcomes after approximately 90 days of second- or later-line valsartan treatment. Hierarchical linear and logistic regressions were applied to identify determinants of BP outcomes. Similar reductions in BP values and similar BP control rates were achieved in both groups after

International journal of chronic diseases2017 Full Text: Link to full Text with Trip Pro

12. Entresto (sacubitril, valsartan) - treatment of heart failure

Entresto (sacubitril, valsartan) - treatment of heart failure Entresto (sacubitril, valsartan) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Entresto (sacubitril, valsartan) Conclusion Entresto is the first medicine in the class of combined angiotensin receptor neprilysin inhibitors (ARNI) containing valsartan and sacubitril. It is indicated for the treatment of heart failure as an alternative to angiotensin converting enzyme (ACE

Danish Pharmacotherapy Reviews2017

13. Sacubitril + valsartan (Entresto) in chronic heart failure. Favourable results in highly selected patients

Sacubitril + valsartan (Entresto) in chronic heart failure. Favourable results in highly selected patients Prescrire IN ENGLISH - Spotlight ''Sacubitril + valsartan (Entresto°) in chronic heart failure. Favourable results in highly selected patients'', 1 February 2017 {1} {1} {1} | | > > > Sacubitril + valsartan (Entresto°) in chronic heart failure. Favourable results in highly selected patients Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |    (...) |   |   |   |   |   |   |   |  Spotlight Sacubitril + valsartan (Entresto°) in chronic heart failure. Favourable results in highly selected patients FEATURED REVIEW Replacing an ACE inhibitor or an ARB with the high-dose sacubitril + valsartan combination should be envisaged with care, and solely for heart failure patients comparable to those included in the only available trial. Most chronic heart failure patients should continue to use

Prescrire2017

15. ENTRESTO - Sacubitril/valsartan (as sacubitril valsartan sodium hydrate complex)

ENTRESTO - Sacubitril/valsartan (as sacubitril valsartan sodium hydrate complex) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after

Health Canada - Drug and Health Product Register2017

16. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. 27842179 2016 11 14 2017 02 03 2380-6591 2 1 2017 Jan 01 JAMA cardiology JAMA Cardiol Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF (...) is reduced by sacubitril/valsartan in comparison with enalapril. The PARADIGM-HF (Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial randomly assigned 8399 patients with chronic HF, New York Heart Association class II to IV symptoms, and a left ventricular EF of 40% or less to treatment with enalapril 10 mg twice daily or sacubitril/valsartan 97/103 mg twice daily (previously known as LCZ696 [200 mg twice daily]) in addition

JAMA cardiology2016

18. Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.

Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction. Background: Sacubitril-valsartan therapy reduces cardiovascular mortality compared with enalapril therapy in patients with heart failure with reduced ejection fraction. Objective: To evaluate the cost-effectiveness of sacubitril-valsartan versus angiotensin-converting enzyme inhibitor therapy in patients with chronic heart failure. Design: Markov decision model. Data Sources: Clinical (...) trials, observational analyses, reimbursement data from the Centers for Medicare & Medicaid Services, drug pricing databases, and Centers for Disease Control and Prevention life tables. Target Population: Patients at an average age of 64 years, New York Heart Association (NYHA) class II to IV heart failure, and left ventricular ejection fraction of 0.40 or less. Time Horizon: Lifetime. Perspective: Societal. Intervention: Treatment with sacubitril-valsartan or lisinopril. Outcome Measures: Life

Annals of Internal Medicine2016

19. Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study

Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study 27747834 2018 11 13 2199-1154 3 3 2016 Sep Drugs - real world outcomes Drugs Real World Outcomes Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study. 307-315 EXCITE (clinical experience of amlodipine and valsartan in hypertension) evaluated the (...) real-world effectiveness and safety of single-pill combinations (SPCs) of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) in patients with hypertension from the Middle East and Asia. The objective of this study was to report the results of EXCITE study from Egypt, where all patients were prescribed Aml/Val. This was a 26-week, observational, multicenter, prospective, non-interventional, open-label study. Effectiveness was assessed as change in the mean

Drugs - real world outcomes2016 Full Text: Link to full Text with Trip Pro

20. [Sacubitril/valsartan: addendum to commission A15-60]

[Sacubitril/valsartan: addendum to commission A15-60] Sacubitril/Valsartan: addendum zum auftrag A15-60; auftrag A16-29 [Sacubitril/valsartan: addendum to commission A15-60] Sacubitril/Valsartan: addendum zum auftrag A15-60; auftrag A16-29 [Sacubitril/valsartan: addendum to commission A15-60] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sacubitril/Valsartan: addendum zum auftrag A15-60; auftrag A16-29. [Sacubitril/valsartan: addendum to commission A15-60] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 394. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Tetrazoles; Valine; Valsartan Language Published

Health Technology Assessment (HTA) Database.2016